<DOC>
	<DOCNO>NCT01772225</DOCNO>
	<brief_summary>The aim observational study identify quantify humanistic economic burden illness patient complete resection ( residual disease ) stage IB-IIIA NSCLC three European country ( France , Germany , United Kingdom [ UK ] ) . Data collection conduct patient medical record abstraction patient survey .</brief_summary>
	<brief_title>NSCLC Burden Illness Study</brief_title>
	<detailed_description>The study procedure effect medical care deliver enrol patient . Physicians continue provide usual medical care patient . There study intervention , drug intervention provide site part study . Methodology : study consist two component : - Medical record abstraction . Medical record eligible patient ( live decease ) review , data extract study . Data collect include patient demographic disease characteristic , detail medical care receive ( include adjuvant treatment ) , information disease recurrence/progression . - Patient survey . Living patient asked participate patient survey . Living patient agree participate administered brief patient questionnaire collect information available clinical site ' medical record [ e.g. , local medical care , patient out-of-pocket expense , work loss , health-related quality life ( HRQOL ) ] . The site may exclude individual patient survey site staff feel would inappropriate individual ; study collect patient survey information family decease patient . Informed consent collect living patient participate patient survey , apart abstraction medical record . Country-specific requirement follow . The medical record patient ( live decease ) complete resection stage IB-IIIA NSCLC 01 August 2009 31 July 2012 identify . No vaccine drug administer study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Patient medical record screen use follow criterion : Patients must age 18 year old time first presentation clinical stage IBIIIA NSCLC . Patients must complete resection pathologic stage IBIIIA NSCLC least 1 calendar month prior date screening , accord current classification recommend International Association Study Lung Cancer ( 2009 ) . The investigator/study site must main care provider patient period treatment management patient 's NSCLC . Patients underwent wedge resection . Patients whose resection le 1 calendar month date screening . Patients receive adjuvant systemic treatment within clinical trial type adjuvant treatment either unknown recommend international clinical guideline [ European Society Medical Oncology ( ESMO ) , National Comprehensive Cancer Network ( NCCN ) ] . Patients lose followup : Living patient longer care site longer contact . Deceased patient transfer another NSCLC treatment centre death . Patients concomitant malignancy receive treatment cancer time treatment followup NSCLC .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Observational Retrospective</keyword>
	<keyword>Health-related quality life ( HRQoL )</keyword>
	<keyword>Patients</keyword>
	<keyword>Stage IB-IIIA</keyword>
	<keyword>Burden Illness</keyword>
	<keyword>Non-small Cell Lung Cancer ( NSCLC )</keyword>
</DOC>